Image

CLABSI Prevention With Tissue Adhesive

CLABSI Prevention With Tissue Adhesive

Recruiting
18 years and younger
All
Phase N/A

Powered by AI

Overview

Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.

Description

Health-care associated infections (HAI) and especially central-line associated blood stream infections (CLABSI) are a well described burden in the intensive care units. There are two main possible pathways leading to central-venous line (CVL) related infection: the first is migration of microbes down the catheter tract (between the CVL and the skin), and the second is via the catheter hub/lumen. Cyanoacrylate adhesive is a commonly used tissue adhesive in children and adults with frequent use in pediatric facial lacerations. Several studies have shown its feasibility and safety in the general pediatric population, including neonates and in children after cardiac surgery.

To our knowledge, no study to date has explored the use of 2-octyl cyanoacrylate at central-line exit site as a mean to decreases pediatric CLABSI.

Our aim is to assess 2-octyl cyanoacrylate association with CLABSI rate in pediatric cardiac intensive care population.

Eligibility

Inclusion Criteria:

        All patients admitted to pediatric cardiac ICU (PCICU) defined as high-risk for CLABSI (any
        of):
          -  young age<1y & Congenital Heart Surgery Mortality Category (STAT\STS-EACTS) score 2-5
          -  Risk Adjustment for Congenital Heart Surgery (RACHS) category ≥3
          -  preoperative length-of-stay (LOS) >7 days
          -  preoperative ventilator support
          -  presence of a genetic abnormality
          -  extracorporeal membrane oxygenation (ECMO) support
        Exclusion Criteria:
          -  Patients with on-going bacteremia
          -  patients with pre-existing central-line or peripherally inserted central catheter
             (PICC)
          -  parental refusal to participate.

Study details
    Central-line Associated Blood Stream Infections (CLABSI)

NCT05721677

Rabin Medical Center

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.